Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Take Advantage of Using HSA and FSA Accounts at Our Clinics At AquaVitae, were committed to keeping you informed about the latest advancements in health and wellness
-Six months of needle therapy, Roche/Alnylam's new SiRNA antihypertensive drug is planned to be included in breakthrough therapies On June 2, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Roche's Zilebesiran is intended to be included as a breakthrough therapy for adult hypertensive patients with cardiovascular disease or high risk of cardiovascular disease, in order to reduce the risk of cardiovascular death, non fatal myocardial infarction, non fatal stroke, and heart failure events (hospitalization or emergency treatment for heart failure)
A patient paying $199/month at 0.25mg may pay $349/month or more once they reach a 1.7mg maintenance dose
Most experts say up to 500 mg per day for a couple of months is generally well tolerated.
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
